FAQ: Quantum BioPharma's CVR Distribution and Litigation Update
Summary
Quantum BioPharma has set October 27, 2025 as the record date for distributing contingent value rights (CVRs) to Class B shareholders, which entitle holders to a portion of potential litigation proceeds exceeding $700 million against major financial institutions.
What is the main announcement from Quantum BioPharma?
Quantum BioPharma has established October 27, 2025 as the record date for distributing contingent value rights (CVRs) to holders of its Class B Subordinate Voting Shares on a one-for-one basis.
What are the CVRs and what do they entitle shareholders to?
Each CVR entitles holders to a pro rata portion of between 10% and 50% of any net proceeds ultimately recovered from the company’s ongoing litigation against CIBC World Markets, RBC Dominion Securities, and others, which seeks damages exceeding USD $700 million.
When is the record date for the CVR distribution?
The record date for the CVR distribution is October 27, 2025.
What are the key characteristics of these CVRs?
The CVRs are non-transferable, carry no interest or voting rights, and will only be redeemable for cash if Qualifying Net Proceeds are received through settlement or a final, non-appealable judgment.
Who is involved in the litigation that the CVRs are tied to?
The litigation is against CIBC World Markets, RBC Dominion Securities, and others, with the company seeking damages exceeding USD $700 million.
What is Quantum BioPharma’s primary business focus?
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders.
What is Lucid-MS and who is developing it?
Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models, and is being developed through Quantum BioPharma’s wholly owned subsidiary, Lucid Psycheceuticals Inc.
What is Quantum BioPharma’s relationship with Unbuzzd Wellness Inc.?
Quantum BioPharma retains ownership of 20.11% of Unbuzzd Wellness Inc. and receives royalty payments of 7% of sales from unbuzzd(TM) until payments total $250 million, after which the royalty drops to 3% in perpetuity, while retaining 100% rights for pharmaceutical and medical uses.
Where can investors find more information about Quantum BioPharma?
The latest news and updates relating to QNTM are available in the company’s newsroom at https://www.investorbrandnetwork.com/clients/quantum-biopharma-ltd/
What other business activities does Quantum BioPharma engage in?
Through its wholly owned subsidiary, FSD Strategic Investments Inc., Quantum BioPharma maintains a portfolio of strategic investments representing loans secured by residential or commercial property.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 242579